bioRxiv ScienceSearch

Biology subjects

Otte, W. M.

Publications and source records attributed to Otte, W. M..

2 recordsLinked to original sources

Reliable and automatic epilepsy classification with affordable, consumer-grade electroencephalography in rural sub-Saharan Africa

Epilepsy is largely under-diagnosed in low-income and middle-income countries, due to lack of medical specialists and expensive electroencephalography (EEG) hardware. In this study we investigate if low-cost consumer-grade EEG in combination with machine learning techniques can offer a reliable screening tool to improve diagnosis rates.\n\nWe acquired brain signals in people with epilepsy (N=163) and healthy controls (N=138) in two difficult-to-reach areas in rural Guinea-Bissau and Nigeria. Five minutes of fourteen channel resting-state EEG data were acquired with a portable, low-cost consumer-grade EEG recording headset. EEG channel time-series were divided in four-second artifact-free epochs and transformed into delta, theta, alpha, beta and gamma wavelet frequencies. Summary measures such as the mean, standard deviation, minimal value and maximal value of the epoch signal fluctuations were used to train a random forest classifier. Epilepsy diagnosis based on at least three months seizure calendar data was used as the gold standard diagnosis. To prevent too optimistic classification the trained model was evaluated with EEG data from subjects not used in the training. In addition, we tested a classification model trained on Nigeria data against data from people in Guinea-Bissau and vice versa. The most contributing data features in the EEG were found in the beta and theta frequencies in Guinea-Bissau and Nigeria, respectively. Within-country model performance was good with area under the receiver-operating curves of 0.85 and 0.78 ({+/-} 0.02 standard errors) in unseen data in Guinea-Bissau and Nigeria, respectively. Across-country performance was moderate (0.62 and 0.64 {+/-} 0.02).\n\nOur data suggests that a combination of low cost electroencephalography and machine learning techniques may facilitate diagnostic screening for epilepsy in the most remote areas of the world.

neuroscience

Statistical power of clinical trials has increased whilst effect size remained stable: an empirical analysis of 137 032 clinical trials between 1975-2017

BackgroundBiomedical studies with low statistical power are a major concern in the scientific community and are one of the underlying reasons for the reproducibility crisis in science. If randomized clinical trials, which are considered the backbone of evidence-based medicine, also suffer from low power, this could affect medical practice.\n\nMethodsWe analysed the statistical power in 137 032 clinical trials between 1975 and 2017 extracted from meta-analyses from the Cochrane database of systematic reviews. We determined study power to detect standardized effect sizes according to Cohen, and in meta-analysis with p-value below 0.05 we based power on the meta-analysed effect size. Average power, effect size and temporal patterns were examined.\n\nResultsThe number of trials with power [≥]80% was low but increased over time: from 9% in 1975-1979 to 15% in 2010-2014. This increase was mainly due to increasing sample sizes, whilst effect sizes remained stable with a median Cohens h of 0.21 (IQR 0.12-0.36) and a median Cohens d of 0.31 (0.19-0.51). The proportion of trials with power of at least 80% to detect a standardized effect size of 0.2 (small), 0.5 (moderate) and 0.8 (large) was 7%, 48% and 81%, respectively.\n\nConclusionsThis study demonstrates that sufficient power in clinical trials is still problematic, although the situation is slowly improving. Our data encourages further efforts to increase statistical power in clinical trials to guarantee rigorous and reproducible evidence-based medicine.

epidemiology